0001628280-23-036463.txt : 20231102 0001628280-23-036463.hdr.sgml : 20231102 20231102165902 ACCESSION NUMBER: 0001628280-23-036463 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231031 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taveras Arthur CENTRAL INDEX KEY: 0001830901 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 231373382 MAIL ADDRESS: STREET 1: C/O X4 PHARMACEUTICALS, INC. STREET 2: 61 NORTH BEACON STREET, 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wk-form4_1698958731.xml FORM 4 X0508 4 2023-10-31 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001830901 Taveras Arthur C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 0 1 0 0 Chief Scientific Officer 0 Common Stock 2023-10-31 4 A 0 230645 0 A 317018 D Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. /s/ Adam S. Mostafa, attorney-in-fact 2023-11-02